{
  "symbol": "CCCC",
  "company_name": "C4 Therapeutics Inc",
  "ir_website": "https://ir.c4therapeutics.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors",
          "url": "https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-appoints-accomplished-oncology-executive-steve",
          "content": "[Skip to content](#lfg-main-content)\n\n[![C4 Therapeutics, Inc.](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/C4Therapeutics-Website-Logo-FullColor.svg)](https://c4therapeutics.com/)\n\n[ menu ](#)\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/ )\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Presentations and Publications](https://c4therapeutics.com/our-science/scientific-presentations-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Expanded Access Program](https://c4therapeutics.com/our-pipeline/expanded-access-program/)\n  * [Our Company](https://c4therapeutics.com/our-company/)\n    * [Overview](https://c4therapeutics.com/our-company/)\n    * [Leadership Team](https://c4therapeutics.com/our-company/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/our-company/board-of-directors/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Publications](https://c4therapeutics.com/our-science/scientific-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Who We Are](https://c4therapeutics.com/who-we-are/)\n    * [Overview](https://c4therapeutics.com/who-we-are/)\n    * [Leadership Team](https://c4therapeutics.com/who-we-are/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/who-we-are/board-of-directors/)\n    * [Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/)\n    * [Clinical Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/#cab)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n\n[ close ](#)\n\n# Release Details\n\n## \n\nC4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors\n\nNovember 20, 2024\n\n[PDF Version](/node/10186/pdf)\n\n_Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience_\n\n_Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress_\n\nWATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director.\n\n“Our commitment to assembling a group of industry experts who offer diverse perspectives to our Board has resulted in bringing on some of the industry’s brightest minds, from leaders in asset discovery, to discovery, clinical development and corporate governance experts. As we continue advancing our portfolio of novel degraders, on behalf of the Board, I am thrilled to welcome Steve Hoerter and his deep product commercialization experience,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “Steve’s proven expertise in strategically advancing oncology programs into the commercial market will help guide our plans to become a fully integrated biotechnology company bringing innovative small molecule degraders to patients.”\n\nMr. Hoerter has over three decades of executive management, commercial and board experience, most recently serving as the president and chief executive officer of Deciphera Pharmaceuticals, which was acquired by ONO Pharmaceutical for $2.4 billion in June 2024. He transformed Deciphera from a clinical-stage company into a fully integrated global organization with the successful approval and launch of QINLOCK® for the treatment of advanced gastrointestinal stromal tumors in the U.S. and Europe, while advancing the company’s pipeline of novel product candidates. Prior to Deciphera, he was chief commercial officer of Agios Pharmaceuticals, where he was responsible for building the company’s commercial organization to enable the launches of its first two approved products in the U.S., TIBSOVO® and IDHIFA®, both for the treatment of acute myeloid leukemia. Earlier in his career, he served as chief commercial officer of Clovis Oncology and held general management and commercial roles at Roche, Genentech, Chiron Corporation (acquired by Novartis) and Eli Lilly and Company. Mr. Hoerter is on the Board of Directors of ORIC Pharmaceuticals, a clinical-stage oncology company, and has previously served on the Boards of Constellation Pharmaceuticals (acquired by MorphoSys), Deciphera Pharmaceuticals and Ignyta (acquired by Roche). He earned his B.A. from Bucknell University, his M.B.A. from Tilburg University in the Netherlands and an M.S. in management from the Krannert School of Management at Purdue University.\n\n“I am excited to join the C4T Board as the Company advances its pipeline of novel targeted protein degraders that have the potential to disrupt the treatment landscape and improve outcomes for patients,” said Mr. Hoerter. “C4T is a leader in the field of targeted protein degradation, with a rich pipeline of orally bioavailable small-molecule degraders targeting challenging cancer targets with significant unmet needs. I look forward to supporting C4T’s continued evolution as it advances new therapies for patients.”\n\n![Steve Hoerter](https://ml.globenewswire.com/Resource/Download/88557d93-0141-431c-8c90-9ab9e3a3a8f5/steve-hoerter.jpg)\n\n**About C4 Therapeutics** C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit [www.c4therapeutics.com](https://www.globenewswire.com/Tracker?data=y0zFYecLNa6pkunN_16HYVAX-AOrZJl1CzVwxgIFj9mGAhaHoBUPSoqWAT0scE3WxEMAkDtMA-aQB-CwS4qWysa5pzt5jOTWITLYaTY8gxo=).\n\n**Contacts:**\n\nInvestors:Courtney SolbergSenior Manager, Investor RelationsCSolberg@c4therapeutics.com\n\nMedia:Loraine SpreenSenior Director, Corporate Communications & Patient Advocacy[LSpreen@c4therapeutics.com](https://www.globenewswire.com/Tracker?data=s7x30Z3yMqM4Mb-gW6__P1CtQOXboOrFpvT3-Jo2Y_5dhdu4jd5ksxXXGKev2UTeYKcxjUaV640Reh0DQ_wAJXodgfV03820pwCBd8txvqNSQBqyngxq4UDhRugwV45R)\n\nA photo accompanying this announcement is available at [https://www.globenewswire.com/NewsRoom/AttachmentNg/88557d93-0141-431c-8c90-9ab9e3a3a8f5](https://www.globenewswire.com/Tracker?data=5lOPrhFvnAoQQrXPi37K8741rF382iqSRG51z-fvCBmR1VZMMT6RKWRavVVCbC0d4Ue0RKkpfEZ9X8JmutAO23JFEGsJliZWwxWhb-nz521uybgxHCch4ou3m3BnDM2PUyhgM49tQ8s64ltwoWLUpjBz6bZauDj-EReF7UG938l76toYuT4hGEbfi6gkCvBnVvPpivBBDKUfmkT2Co9jM5RwBYj6nYQn_Qfgl691yROOPGImrFwy9sBtdwsbFHMf1ctQVoOYH1X4VuPQo0DyUA==).\n\n![](https://ml.globenewswire.com/media/YjMzNWI1NjgtNWM5Mi00NDhmLWI3MWYtNzg3ZTc4Mjk5N2Y0LTEyMTE5NDA=/tiny/C4-Therapeutics-Inc-.png)\n\n![Image Description](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/221103_C4Therapeutics_HiRes-8503.jpg)\n\n[ ](#footer)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://twitter.com/C4Therapeutics)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://www.linkedin.com/company/c4-therapeutics-inc./)\n"
        },
        {
          "title": "C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial",
          "url": "https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-first-patient-dosed-cft8919-clinical",
          "content": "[Skip to content](#lfg-main-content)\n\n[![C4 Therapeutics, Inc.](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/C4Therapeutics-Website-Logo-FullColor.svg)](https://c4therapeutics.com/)\n\n[ menu ](#)\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/ )\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Presentations and Publications](https://c4therapeutics.com/our-science/scientific-presentations-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Expanded Access Program](https://c4therapeutics.com/our-pipeline/expanded-access-program/)\n  * [Our Company](https://c4therapeutics.com/our-company/)\n    * [Overview](https://c4therapeutics.com/our-company/)\n    * [Leadership Team](https://c4therapeutics.com/our-company/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/our-company/board-of-directors/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Publications](https://c4therapeutics.com/our-science/scientific-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Who We Are](https://c4therapeutics.com/who-we-are/)\n    * [Overview](https://c4therapeutics.com/who-we-are/)\n    * [Leadership Team](https://c4therapeutics.com/who-we-are/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/who-we-are/board-of-directors/)\n    * [Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/)\n    * [Clinical Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/#cab)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n\n[ close ](#)\n\n# Release Details\n\n## \n\nC4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial\n\nNovember 6, 2024\n\n[PDF Version](/node/10081/pdf)\n\n### Clinical Development Initiated in Greater China by Partner Betta Pharmaceuticals\n\nWATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable allosteric degrader of EGFR L858R for non-small cell lung cancer (NSCLC), in Greater China.\n\n“We are pleased to see CFT8919, our fourth small molecule degrader to enter the clinic, begin the journey through clinical development in Greater China with our partner Betta Pharmaceuticals,” said Len Reyno, M.D., chief medical officer of C4 Therapeutics. “CFT8919 may offer an exciting advancement in treating non-small cell lung cancer driven by an EGFR mutation, which is currently treated with EGFR tyrosine kinase inhibitors (TKIs) that offer a less durable response for patients with the EGFR L858R driver mutation than those with other driver mutations. We, along with our partner Betta Pharmaceuticals, believe CFT8919 may offer a novel targeted therapy for patients and physicians searching for treatment options.”\n\nC4T designed CFT8919 to be potent and selective against EGFR bearing an oncogenic L858R mutation and capable of overcoming common EGFR secondary mutations that render patients refractory to EGFR TKIs. The EGFR mutation is particularly common in NSCLC patients of Asian heritage. In China, where approximately 693,000 patients are diagnosed with NSCLC annually, approximately 50 percent of diagnoses are driven by the EGFR mutation. The EGFR L858R mutation is the second most common EGFR mutation, found in approximately 40 percent of patients diagnosed with an EGFR mutation in the U.S. and China.\n\nIn 2023, C4T and Betta Pharmaceuticals entered into a strategic collaboration to develop, manufacture and commercialize CFT8919 in Greater China, including Hong Kong SAR, Macau SAR and Taiwan. Under the terms of the agreement, C4T is eligible for up to $357 million in potential milestones plus royalties on net sales. C4T retains development and commercialization rights for CFT8919 in the United States, European Union and rest of the world.\n\n**About CFT8919** CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in  _in vitro_ and  _in vivo_ models of L858R driven non-small cell lung cancer. Importantly, CFT8919 retains full activity against additional EGFR mutations that confer resistance against approved EGFR inhibitors including L858R-C797S, L858R-T790M, and L858R-T790M-C797S.\n\n**About C4 Therapeutics** C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit [www.c4therapeutics.com](https://www.globenewswire.com/Tracker?data=huf8vLAfP92hbzEbny7TanSDIIF80HyZ3QVbbMlc32HV-vkKX72KLXPeE4gFhXL0QA1nPM-EzgRAGLtQx8AZo0Rh5DZCXB9B9DP0qjQc4xHSKM_YGV8ptnkNTL7nzTKcU6cxs66-rt8SSmPmtC6oX06q35pNv9NhTS-UeBq9akKPOhRX_bVm4CzYXAUYaIdX88hGLyEEtXVuGqObr6Bm2woqPWATOBfffir8oIMYfwCqn0v6BsV_p3iJH6zofy6Rfux5Ompt_ucO2s0B3fym2AwoMFvKPBTGJw9ebzX-e0TmLD5EydtYiSbVNSPpB46UMDT_17D7oN-bvJiYAXZYsDekSc1yc-aAdQTMloc4rxVZ8pE7AGaQ040BTXUqqfhFU63OpmC_EZzyZ36QaDeMej7e52C5diUGcDsLGDANPQMml6R2sqWIIK92f5fHjzXDkeRRlY0fT4iRsEY7A7RxyDZ-kmr99Mj6rywLjpPgURyd7zVQz-bYkjqWwNOtKE57z9C57ajG1S0CLjeuzo01rG4p8qd6d75sA-0h0s5Zolv-1QyUGVnoIAMNQQoQdWiJxp9ltk1RIphiJoXC4fvVfEEA_VW3IqFdtQgmw2TBPwHWRSXrgwbYgD7IzDxBDq4yBFP8DFeTaABvMgMczNvzBhNKeLqdMLUsiKcq_3m0HGvMr-cBylUTm8QPLc_-NDHhGjo2go2qq3SrcRTBWaOYanm4fqeDJN74ZRO8Fe0phLlebYqlQCxjkK9VYyl0xhJC2BUrZX8oCJH8ObksTVIR2j481LGvCn2Jvs97U24bzxc=).\n\n**Forward-Looking Statements** This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; our ability to achieve milestones and receive potential royalty payments from our collaboration partner, Betta Pharmaceuticals; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.\n\n**Contacts:** Investors:Courtney SolbergSenior Manager, Investor RelationsCSolberg@c4therapeutics.com\n\nMedia:Loraine SpreenSenior Director, Corporate Communications & Patient AdvocacyLSpreen@c4therapeutics.com\n\n![](https://ml.globenewswire.com/media/MzJhNDY2ZTYtZDVmYy00NTUzLWE0MmEtOWQ0YzRlMTMwNzZkLTEyMTE5NDA=/tiny/C4-Therapeutics-Inc-.png)\n\n![Image Description](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/221103_C4Therapeutics_HiRes-8503.jpg)\n\n[ ](#footer)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://twitter.com/C4Therapeutics)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://www.linkedin.com/company/c4-therapeutics-inc./)\n"
        },
        {
          "title": "C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting",
          "url": "https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-present-data-ongoing-phase-12-trial-cemsidomide",
          "content": "[Skip to content](#lfg-main-content)\n\n[![C4 Therapeutics, Inc.](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/C4Therapeutics-Website-Logo-FullColor.svg)](https://c4therapeutics.com/)\n\n[ menu ](#)\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/ )\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Presentations and Publications](https://c4therapeutics.com/our-science/scientific-presentations-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Expanded Access Program](https://c4therapeutics.com/our-pipeline/expanded-access-program/)\n  * [Our Company](https://c4therapeutics.com/our-company/)\n    * [Overview](https://c4therapeutics.com/our-company/)\n    * [Leadership Team](https://c4therapeutics.com/our-company/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/our-company/board-of-directors/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Publications](https://c4therapeutics.com/our-science/scientific-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Who We Are](https://c4therapeutics.com/who-we-are/)\n    * [Overview](https://c4therapeutics.com/who-we-are/)\n    * [Leadership Team](https://c4therapeutics.com/who-we-are/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/who-we-are/board-of-directors/)\n    * [Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/)\n    * [Clinical Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/#cab)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n\n[ close ](#)\n\n# Release Details\n\n## \n\nC4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting\n\nNovember 5, 2024\n\n[PDF Version](/node/10066/pdf)\n\n### C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET)\n\nWATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that two abstracts from the ongoing Phase 1/2 trial of cemsidomide have been accepted for presentation at the ASH Annual Meeting taking place from December 7 – 10, 2024 in San Diego, California. Non-Hodgkin’s lymphoma (NHL) data will be shared as an oral presentation and multiple myeloma (MM) data will be shared as a poster presentation. The abstracts are available online on the ASH Annual Meeting [website](https://www.globenewswire.com/Tracker?data=haeHLeK4MN9vLSdfzI5ZEuj26Oawn1CPrM7YBoIZqrj0znpl4s4XWvvVmsDxjS_xZF9Jj9pyTNmpHaY3BBkWNnSwPhnEzh5bv-SyqzK2ZpTCs-k3T0TlDbIYZrMjp41a).\n\nThe presentations on December 8th at the ASH Annual Meeting will include updated data compared to the abstracts.\n\n**NHL Oral Presentation Details:**\n\n**Title:** Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, in Patients with Non-Hodgkin’s Lymphoma**Format** : Oral (10-minute presentation, followed by a 5-minute discussion)**Session:** T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas **Session Date:** Sunday, December 8, 2024**Presentation Time:** 10:30 AM PT (1:30 PM ET)**Location:** San Diego Convention Center, Ballroom 20CD\n\n**MM Poster Presentation Details:**\n\n**Title:** Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma**Format** : Poster presentation**Session:** Multiple Myeloma: Pharmacologic Therapies: Poster II **Session Date:** Sunday, December 8, 2024 **Presentation Time:** 6:00 PM - 8:00 PM PT (9 PM – 11 PM ET)**Location:** San Diego Convention Center, Halls G-H**Publication Number:** 3366\n\n**_C4T Investor Webcast_**\n\nC4T will host a webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET). A live webcast of the event will be available using [this link](https://www.globenewswire.com/Tracker?data=cFz2GGWoaHa6SZ1Ll-cQH07shozGgJczXVgz_-Yhgcu41YAE8gJ0SxN15ObS3Op_gyREyaXz4qBaYkLasE8ihsAXp8oZoNgB5fjMJK2B3y8=) or under the “Events & Presentations” page of the Investors section on the company’s website at [www.c4therapeutics.com](https://www.globenewswire.com/Tracker?data=sR8HyVPHqrV1-TuMhdfPCEqDyEKhbUG5SJeJnPfI_LcVzHSU0UnFdGyWJmksT5Br8KhN2xbJUbuK6cUYhgJlP78d7EcI5j2dI5sH4GN_GBc=). A replay of the webcast will be archived and available following the event.\n\n**About C4 Therapeutics**\n\nC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit [www.c4therapeutics.com](https://www.globenewswire.com/Tracker?data=sR8HyVPHqrV1-TuMhdfPCEqDyEKhbUG5SJeJnPfI_Lf_xhMJ6AH5U4E37EaIEw3ew9pe3BWGIgezRJ9SxpN05wY_MLifLHfGrCSKD4IvZeY=).\n\n**About Cemsidomide**\n\nCemsidomide is an orally bioavailable MonoDAC® degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Cemsidomide is currently in a Phase 1 dose escalation study in MM and NHL. Initial clinical data show cemsidomide is well-tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects. More information about this trial may be accessed at [www.clinicaltrials.gov](https://www.globenewswire.com/Tracker?data=sR8HyVPHqrV1-TuMhdfPCD42d2SGQ-s28m0ZSzUm2Vk-XMv-sWpM9mVHRMa5F--22V3Cgu9irhE9JyFVsJyl5BugJsQuKp5dV-kqxlddGE0vW1VlTEa647X7y-n0eEOZ6JGiwGR0j1MfkyE9-UEkiWjf9y2Fq42PTOgRXyLb2KMqqGkGtoMb9zhO62N6Jh2XzdZiVGkjgGuy1Jz0r0pr5m0YA_00pDvYbjwUL3qZDlUm79Uv-LDrnWER-YJV3qGffmqgR9mFo06Dk9KRzwkWkg==) (identifier: NCT04756726).\n\n**Contacts:**\n\nInvestors:Courtney SolbergSenior Manager, Investor Relations[CSolberg@c4therapeutics.com](https://www.globenewswire.com/Tracker?data=SUEvMN9wdN2PXJiHlKaiY4y_n2hwtetvXjdZu80RK3VSdeEHXUm5f9rJmd_6OmAsSWmlTvFkHMo0yKKE5YWweavD-w5Y58gTeF6c3gZCtdxlK9plULamcDmyij_1ZFUo)\n\nMedia:Loraine SpreenSenior Director, Corporate Communications & Patient Advocacy[LSpreen@c4therapeutics.com](https://www.globenewswire.com/Tracker?data=f9BpRTD_Inf6McY8_X7PUSQ9aN8k0OV6UXPrr7foxSm6_VTYGc2jH3f8MVb6pLt6rCp0_oftv5d-l4sPU5qOZyJFSdVFrTBL3egNNdvCyBHC0qHmoSBJaRe0JrMPvI6w)\n\n![](https://ml.globenewswire.com/media/MzNmNzNmZmUtNDI2Ni00NDA2LWJkZTgtZjM2ZDg2MTViNjgyLTEyMTE5NDA=/tiny/C4-Therapeutics-Inc-.png)\n\n![Image Description](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/221103_C4Therapeutics_HiRes-8503.jpg)\n\n[ ](#footer)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://twitter.com/C4Therapeutics)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://www.linkedin.com/company/c4-therapeutics-inc./)\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Updated Data in Multiple Myeloma and First Data in non-Hodgkin’s Lymphoma from the Ongoing Phase 1/2 Trial of Cemsidomide Presented at ASH 2024",
          "url": "https://ir.c4therapeutics.com/events/event-details/updated-data-multiple-myeloma-and-first-data-non-hodgkins-lymphoma-ongoing",
          "content": "[Skip to content](#lfg-main-content)\n\n[![C4 Therapeutics, Inc.](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/C4Therapeutics-Website-Logo-FullColor.svg)](https://c4therapeutics.com/)\n\n[ menu ](#)\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/ )\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Presentations and Publications](https://c4therapeutics.com/our-science/scientific-presentations-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Expanded Access Program](https://c4therapeutics.com/our-pipeline/expanded-access-program/)\n  * [Our Company](https://c4therapeutics.com/our-company/)\n    * [Overview](https://c4therapeutics.com/our-company/)\n    * [Leadership Team](https://c4therapeutics.com/our-company/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/our-company/board-of-directors/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Publications](https://c4therapeutics.com/our-science/scientific-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Who We Are](https://c4therapeutics.com/who-we-are/)\n    * [Overview](https://c4therapeutics.com/who-we-are/)\n    * [Leadership Team](https://c4therapeutics.com/who-we-are/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/who-we-are/board-of-directors/)\n    * [Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/)\n    * [Clinical Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/#cab)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n\n[ close ](#)\n\n# Event Details\n\n## Updated Data in Multiple Myeloma and First Data in non-Hodgkin’s Lymphoma from the Ongoing Phase 1/2 Trial of Cemsidomide Presented at ASH 2024\n\nDec 8, 2024 5:00 PM EST\n\n[Click here for Webcast](https://edge.media-server.com/mmc/p/j9bsxb7z/)\n\n[Add to Outlook](/node/10061/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=C4 Therapeutics, Inc. - Updated Data in Multiple Myeloma and First Data in non-Hodgkin’s Lymphoma from the Ongoing Phase 1/2 Trial of Cemsidomide Presented at ASH 2024&dates=20241208T220000Z/20241208T220000Z&details=Event Details: https://ir.c4therapeutics.com/events/event-details/updated-data-multiple-myeloma-and-first-data-non-hodgkins-lymphoma-ongoing%0A%0AWebcast: https://edge.media-server.com/mmc/p/j9bsxb7z/&location=&trp=false&sprop=&sprop=name:)\n\n![Image Description](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/221103_C4Therapeutics_HiRes-8503.jpg)\n\n[ ](#footer)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://twitter.com/C4Therapeutics)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://www.linkedin.com/company/c4-therapeutics-inc./)\n"
        }
      ]
    },
    {
      "section_name": "Upcoming Events",
      "links": [
        {
          "title": "Updated Data in Multiple Myeloma and First Data in non-Hodgkin’s Lymphoma from the Ongoing Phase 1/2 Trial of Cemsidomide Presented at ASH 2024",
          "url": "https://ir.c4therapeutics.com/events/event-details/updated-data-multiple-myeloma-and-first-data-non-hodgkins-lymphoma-ongoing",
          "content": "[Skip to content](#lfg-main-content)\n\n[![C4 Therapeutics, Inc.](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/C4Therapeutics-Website-Logo-FullColor.svg)](https://c4therapeutics.com/)\n\n[ menu ](#)\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/ )\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Presentations and Publications](https://c4therapeutics.com/our-science/scientific-presentations-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Expanded Access Program](https://c4therapeutics.com/our-pipeline/expanded-access-program/)\n  * [Our Company](https://c4therapeutics.com/our-company/)\n    * [Overview](https://c4therapeutics.com/our-company/)\n    * [Leadership Team](https://c4therapeutics.com/our-company/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/our-company/board-of-directors/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Publications](https://c4therapeutics.com/our-science/scientific-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Who We Are](https://c4therapeutics.com/who-we-are/)\n    * [Overview](https://c4therapeutics.com/who-we-are/)\n    * [Leadership Team](https://c4therapeutics.com/who-we-are/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/who-we-are/board-of-directors/)\n    * [Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/)\n    * [Clinical Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/#cab)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n\n[ close ](#)\n\n# Event Details\n\n## Updated Data in Multiple Myeloma and First Data in non-Hodgkin’s Lymphoma from the Ongoing Phase 1/2 Trial of Cemsidomide Presented at ASH 2024\n\nDec 8, 2024 5:00 PM EST\n\n[Click here for Webcast](https://edge.media-server.com/mmc/p/j9bsxb7z/)\n\n[Add to Outlook](/node/10061/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=C4 Therapeutics, Inc. - Updated Data in Multiple Myeloma and First Data in non-Hodgkin’s Lymphoma from the Ongoing Phase 1/2 Trial of Cemsidomide Presented at ASH 2024&dates=20241208T220000Z/20241208T220000Z&details=Event Details: https://ir.c4therapeutics.com/events/event-details/updated-data-multiple-myeloma-and-first-data-non-hodgkins-lymphoma-ongoing%0A%0AWebcast: https://edge.media-server.com/mmc/p/j9bsxb7z/&location=&trp=false&sprop=&sprop=name:)\n\n![Image Description](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/221103_C4Therapeutics_HiRes-8503.jpg)\n\n[ ](#footer)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://twitter.com/C4Therapeutics)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://www.linkedin.com/company/c4-therapeutics-inc./)\n"
        }
      ]
    },
    {
      "section_name": "Past Events",
      "links": [
        {
          "title": "Jefferies London Healthcare Conference",
          "url": "https://ir.c4therapeutics.com/events/event-details/jefferies-london-healthcare-conference-1",
          "content": "[Skip to content](#lfg-main-content)\n\n[![C4 Therapeutics, Inc.](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/C4Therapeutics-Website-Logo-FullColor.svg)](https://c4therapeutics.com/)\n\n[ menu ](#)\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/ )\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Presentations and Publications](https://c4therapeutics.com/our-science/scientific-presentations-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Expanded Access Program](https://c4therapeutics.com/our-pipeline/expanded-access-program/)\n  * [Our Company](https://c4therapeutics.com/our-company/)\n    * [Overview](https://c4therapeutics.com/our-company/)\n    * [Leadership Team](https://c4therapeutics.com/our-company/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/our-company/board-of-directors/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Publications](https://c4therapeutics.com/our-science/scientific-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Who We Are](https://c4therapeutics.com/who-we-are/)\n    * [Overview](https://c4therapeutics.com/who-we-are/)\n    * [Leadership Team](https://c4therapeutics.com/who-we-are/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/who-we-are/board-of-directors/)\n    * [Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/)\n    * [Clinical Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/#cab)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n\n[ close ](#)\n\n# Event Details\n\n## Jefferies London Healthcare Conference\n\nNov 20, 2024 4:00 AM EST\n\n[Click here for Webcast](https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=cccc&url=https%3A//wsw.com/webcast/jeff315/cccc/1799280)\n\n![Image Description](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/221103_C4Therapeutics_HiRes-8503.jpg)\n\n[ ](#footer)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://twitter.com/C4Therapeutics)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://www.linkedin.com/company/c4-therapeutics-inc./)\n"
        },
        {
          "title": "2024 Cantor Global Healthcare Conference",
          "url": "https://ir.c4therapeutics.com/events/event-details/2024-cantor-global-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[![C4 Therapeutics, Inc.](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/C4Therapeutics-Website-Logo-FullColor.svg)](https://c4therapeutics.com/)\n\n[ menu ](#)\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/ )\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Presentations and Publications](https://c4therapeutics.com/our-science/scientific-presentations-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Expanded Access Program](https://c4therapeutics.com/our-pipeline/expanded-access-program/)\n  * [Our Company](https://c4therapeutics.com/our-company/)\n    * [Overview](https://c4therapeutics.com/our-company/)\n    * [Leadership Team](https://c4therapeutics.com/our-company/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/our-company/board-of-directors/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Publications](https://c4therapeutics.com/our-science/scientific-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Who We Are](https://c4therapeutics.com/who-we-are/)\n    * [Overview](https://c4therapeutics.com/who-we-are/)\n    * [Leadership Team](https://c4therapeutics.com/who-we-are/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/who-we-are/board-of-directors/)\n    * [Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/)\n    * [Clinical Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/#cab)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n\n[ close ](#)\n\n# Event Details\n\n## 2024 Cantor Global Healthcare Conference\n\nSep 18, 2024 8:35 AM EDT\n\n[Click here for Webcast](https://wsw.com/webcast/cantor22/cccc/2029860)\n\n![Image Description](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/221103_C4Therapeutics_HiRes-8503.jpg)\n\n[ ](#footer)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://twitter.com/C4Therapeutics)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://www.linkedin.com/company/c4-therapeutics-inc./)\n"
        },
        {
          "title": "Preliminary Monotherapy Results from the Ongoing Phase 1 Trial of CFT1946 Presented at ESMO Congress",
          "url": "https://ir.c4therapeutics.com/events/event-details/preliminary-monotherapy-results-ongoing-phase-1-trial-cft1946-presented-esmo",
          "content": "[Skip to content](#lfg-main-content)\n\n[![C4 Therapeutics, Inc.](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/C4Therapeutics-Website-Logo-FullColor.svg)](https://c4therapeutics.com/)\n\n[ menu ](#)\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/ )\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Presentations and Publications](https://c4therapeutics.com/our-science/scientific-presentations-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Expanded Access Program](https://c4therapeutics.com/our-pipeline/expanded-access-program/)\n  * [Our Company](https://c4therapeutics.com/our-company/)\n    * [Overview](https://c4therapeutics.com/our-company/)\n    * [Leadership Team](https://c4therapeutics.com/our-company/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/our-company/board-of-directors/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n\n  * [Our Science](https://c4therapeutics.com/our-science/)\n    * [Overview](https://c4therapeutics.com/our-science/)\n    * [Learn About Targeted Protein Degradation](https://c4therapeutics.com/our-science/learn-about-targeted-protein-degradation/)\n    * [Harnessing TPD’s Advantages](https://c4therapeutics.com/our-science/harnessing-tpds-advantages/)\n    * [TPD the C4T Way](https://c4therapeutics.com/our-science/tpd-the-c4t-way/)\n    * [TORPEDO® Platform](https://c4therapeutics.com/our-science/torpedo-platform/)\n    * [Focus on Target Selection](https://c4therapeutics.com/our-science/focus-on-target-selection/)\n    * [Scientific Publications](https://c4therapeutics.com/our-science/scientific-publications/)\n  * [Our Pipeline](https://c4therapeutics.com/our-pipeline/)\n    * [Overview](https://c4therapeutics.com/our-pipeline/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n  * [Our Partnerships](https://c4therapeutics.com/our-partnerships/)\n    * [Overview](https://c4therapeutics.com/our-partnerships/)\n    * [Roche](https://c4therapeutics.com/our-partnerships/roche/)\n    * [Biogen](https://c4therapeutics.com/our-partnerships/biogen/)\n    * [Betta](https://c4therapeutics.com/our-partnerships/betta/)\n    * [Merck](https://c4therapeutics.com/our-partnerships/merck/)\n    * [Merck KGaA, Darmstadt, Germany](https://c4therapeutics.com/our-partnerships/merck-kgaa/)\n  * [Who We Are](https://c4therapeutics.com/who-we-are/)\n    * [Overview](https://c4therapeutics.com/who-we-are/)\n    * [Leadership Team](https://c4therapeutics.com/who-we-are/leadership-team/)\n    * [Board of Directors](https://c4therapeutics.com/who-we-are/board-of-directors/)\n    * [Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/)\n    * [Clinical Advisory Board](https://c4therapeutics.com/who-we-are/advisory-board/#cab)\n  * [Life at C4T](https://c4therapeutics.com/life-at-c4t/)\n    * [Overview](https://c4therapeutics.com/life-at-c4t/)\n    * [Our Values](https://c4therapeutics.com/life-at-c4t/our-values/)\n    * [Our People](https://c4therapeutics.com/life-at-c4t/our-people/)\n    * [Deggie’s Room](https://c4therapeutics.com/life-at-c4t/deggies-room/)\n    * [Open Positions](https://c4therapeutics.com/life-at-c4t/open-positions/)\n\n\n  * [Patients & Families](https://c4therapeutics.com/patients-families/)\n    * [Overview](https://c4therapeutics.com/patients-families/)\n    * [Cemsidomide](https://c4therapeutics.com/our-pipeline/cemsidomide/)\n    * [CFT8634](https://c4therapeutics.com/our-pipeline/cft8634/)\n    * [CFT1946](https://c4therapeutics.com/our-pipeline/cft1946/)\n    * [CFT8919](https://c4therapeutics.com/our-pipeline/cft8919/)\n    * [Resources](#)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Healthcare Providers](https://c4therapeutics.com/healthcare-providers/)\n    * [Overview](https://c4therapeutics.com/healthcare-providers/)\n    * [Publications and Resources](https://c4therapeutics.com/our-science/scientific-publications/)\n    * [Expanded Access Program](https://c4therapeutics.com/expanded-access-program/)\n    * [Quality Policy Statement](https://c4therapeutics.com/quality-policy-statement/)\n  * [Investors & Media](#)\n    * [Overview](/)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n    * [Stock Information](/stock-information)\n    * [Analyst Coverage](/analyst-coverage)\n    * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/corporate-governance)\n    * [Email Alerts](/email-alerts)\n    * [Contact IR](/contact-ir)\n    * [FAQs](/faqs)\n\n\n\n[ close ](#)\n\n# Event Details\n\n## Preliminary Monotherapy Results from the Ongoing Phase 1 Trial of CFT1946 Presented at ESMO Congress\n\nSep 13, 2024 12:00 PM EDT\n\n[Click here for Webcast](https://edge.media-server.com/mmc/p/krj586ws/)\n\n### Supporting Materials\n\n[CFT1946 Monotherapy Results from the Ongoing Phase 1 Trial](/static-files/b648e3ae-c2db-4f5e-9d47-324b0c8a2b2b \"CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf\") 1.7 MB\n\n![Image Description](/sites/g/files/knoqqb82551/themes/site/client_site/dist/images/221103_C4Therapeutics_HiRes-8503.jpg)\n\n[ ](#footer)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://twitter.com/C4Therapeutics)\n\n## You are now leaving c4therapeutics.com\n\nYou are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.\n\n[No, I want to stay](#) [Yes, I want to Proceed to the Other Site](https://www.linkedin.com/company/c4-therapeutics-inc./)\n"
        }
      ]
    }
  ]
}